Studies have revealed that a diminished methylation status of the AOX1 gene correlates with a decreased rate of biochemical recurrence and more favorable prognostic outcomes in PCa patients, while further studies have demonstrated that hypermethylation—an epigenetic modification that suppresses AOX1 expression—enhances the migratory and invasive potential of prostate cancer cells, collectively providing compelling evidence that AOX1 functions as a tumor suppressor in PCa [16,17]. Here, AOX1 is linked to prostate cancer.